Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.
Wuxi Biologics reported strong 2025 results, with revenue rising 16.7% to RMB 21.79 billion and net profit jumping 45.3% to RMB 5.73 billion, driven by higher gross margins and robust earnings per share growth, though the board opted against a final dividend. The company’s integrated CRDMO platform and “Follow and Win the Molecule” strategy expanded its project portfolio to 945 ongoing integrated biologics programs, including 74 late-phase and 25 commercial manufacturing projects, reinforcing its position as a preferred global partner and supporting long-term growth momentum across the biologics development and manufacturing value chain.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) Inc. is a contract research, development and manufacturing organization (CRDMO) focused on biologic drugs. The company offers integrated end-to-end services spanning pre-clinical development, clinical phases, and commercial manufacturing for global biotech innovators and multinational pharmaceutical companies.
Average Trading Volume: 34,772,480
Technical Sentiment Signal: Hold
Current Market Cap: HK$134.1B
For detailed information about 2269 stock, go to TipRanks’ Stock Analysis page.